JPH0495062A - Naphthylthioalkylcarboxylic acid derivative - Google Patents
Naphthylthioalkylcarboxylic acid derivativeInfo
- Publication number
- JPH0495062A JPH0495062A JP21189190A JP21189190A JPH0495062A JP H0495062 A JPH0495062 A JP H0495062A JP 21189190 A JP21189190 A JP 21189190A JP 21189190 A JP21189190 A JP 21189190A JP H0495062 A JPH0495062 A JP H0495062A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- group
- alkyl
- acid derivative
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002253 acid Substances 0.000 title abstract description 15
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 16
- -1 N, N-disubstituted carbamoyl Chemical group 0.000 claims abstract description 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 17
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 206010033645 Pancreatitis Diseases 0.000 abstract description 6
- 206010033647 Pancreatitis acute Diseases 0.000 abstract description 6
- 201000003229 acute pancreatitis Diseases 0.000 abstract description 6
- 208000003770 biliary dyskinesia Diseases 0.000 abstract description 6
- 206010009887 colitis Diseases 0.000 abstract description 6
- 102000004859 Cholecystokinin Receptors Human genes 0.000 abstract description 5
- 108090001085 Cholecystokinin Receptors Proteins 0.000 abstract description 5
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 abstract description 3
- 150000001412 amines Chemical class 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- RFCQDOVPMUSZMN-UHFFFAOYSA-N 2-Naphthalenethiol Chemical compound C1=CC=CC2=CC(S)=CC=C21 RFCQDOVPMUSZMN-UHFFFAOYSA-N 0.000 description 3
- BYEHXOQMITZHNP-UHFFFAOYSA-N 5-methoxy-2-(naphthalen-2-ylsulfanylmethyl)-5-oxopentanoic acid Chemical compound C1=CC=CC2=CC(SCC(CCC(=O)OC)C(O)=O)=CC=C21 BYEHXOQMITZHNP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000012156 elution solvent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 3
- NPZLUDUFVKRONY-UHFFFAOYSA-N 2-(naphthalen-2-ylsulfanylmethyl)pentanedioic acid Chemical compound C1=CC=CC2=CC(SCC(CCC(=O)O)C(O)=O)=CC=C21 NPZLUDUFVKRONY-UHFFFAOYSA-N 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WSLPLUSJKBGDRQ-UHFFFAOYSA-N 2-(naphthalen-2-ylsulfanylmethyl)-5-oxo-5-phenylmethoxypentanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1SCC(C(=O)O)CCC(=O)OCC1=CC=CC=C1 WSLPLUSJKBGDRQ-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229940122623 CCK receptor antagonist Drugs 0.000 description 1
- 125000006414 CCl Chemical group ClC* 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 239000002879 Lewis base Substances 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 150000007527 lewis bases Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- WGYDPXQRIKARPE-UHFFFAOYSA-N methyl 5-[3-methoxypropyl(pentyl)amino]-4-(naphthalen-2-ylsulfonylmethyl)-5-oxopentanoate Chemical compound C1=CC=CC2=CC(S(=O)(=O)CC(CCC(=O)OC)C(=O)N(CCCOC)CCCCC)=CC=C21 WGYDPXQRIKARPE-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- JACMPVXHEARCBO-UHFFFAOYSA-N n-pentylpentan-1-amine Chemical compound CCCCCNCCCCC JACMPVXHEARCBO-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- VLQWXUDCWYBQBM-UHFFFAOYSA-M sodium;4-methoxy-2-methylidene-4-oxobutanoate Chemical compound [Na+].COC(=O)CC(=C)C([O-])=O VLQWXUDCWYBQBM-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Abstract
Description
【発明の詳細な説明】
産業上の利用分野
本発明は医薬品の製造中間体として有用な、船人
(式中のR1は水素原子、カルボキシ基、炭素数2〜7
のアルコキシカルボニル基、N−モノ置換またはN、N
−ジ置換カルバモイル基、炭素数1〜6のアルキル基ま
たは炭素数1〜6のアルコキシ基であり 1112は炭
素数1〜10のアルキル基であり、R3は炭素数1〜4
のアルキル基またはベンジル基であり、Yは炭素数1〜
4のアルキレン基であり、nは1または2である)で表
されるナフチルチオアルキルカルボン酸誘導体。DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention is directed to a chemical compound useful as an intermediate for the production of pharmaceuticals, a shipman (where R1 is a hydrogen atom, a carboxy group, and has 2 to 7 carbon atoms).
alkoxycarbonyl group, N-monosubstituted or N,N
- is a disubstituted carbamoyl group, an alkyl group having 1 to 6 carbon atoms, or an alkoxy group having 1 to 6 carbon atoms, 1112 is an alkyl group having 1 to 10 carbon atoms, and R3 is an alkyl group having 1 to 4 carbon atoms.
is an alkyl group or benzyl group, and Y has 1 to 1 carbon atoms.
4 alkylene group, and n is 1 or 2).
(式中のR1は水素原子、カルボキシ基、炭素数2〜7
のアルコキシカルボニル基、N−モノ置換またはN、N
−ジ置換カルバモイル基、炭素数1〜6のアルキル基ま
たは炭素数1〜6のアルコキシ基であす、R2は炭素数
1〜10のアルキル基であり R3は炭素数1〜4のア
ルキル基またはベンジル基であり、Yは炭素数1〜4の
アルキレン基であり、nは1または2である)で表され
るナフチルチオアルキルカルボン酸誘導体に関するもの
である。(R1 in the formula is a hydrogen atom, a carboxy group, and has 2 to 7 carbon atoms.
alkoxycarbonyl group, N-monosubstituted or N,N
-disubstituted carbamoyl group, alkyl group having 1 to 6 carbon atoms, or alkoxy group having 1 to 6 carbon atoms, R2 is an alkyl group having 1 to 10 carbon atoms, and R3 is an alkyl group having 1 to 4 carbon atoms or benzyl Y is an alkylene group having 1 to 4 carbon atoms, and n is 1 or 2).
さらに詳しく述べれば、本発明は、コレシストキニン(
cholecystokinin 、以下CCKという
)受容体拮抗作用を示し、過敏性大腸炎、胆道ジスキネ
ジー、急性膵炎などの疾患の予防および治療剤として有
用な、−船人
(式中のR4は水素原子、炭素数1〜4のアルキル基ま
たはベンジル基であり Rl、R2、Yおよびnは前記
と同じ意味をもつ)であられさるナフチルスルホニルア
ルキルカルボン酸誘導体の製造中間体として有用な一般
式(1)で表されるナフチルチオアルキルカルボン酸誘
導体に関するものである。More specifically, the present invention provides cholecystokinin (
cholecystokinin (hereinafter referred to as CCK) receptor antagonistic activity, and is useful as a prophylactic and therapeutic agent for diseases such as irritable colitis, biliary dyskinesia, and acute pancreatitis. -4 alkyl group or benzyl group, Rl, R2, Y and n have the same meanings as above), represented by the general formula (1) useful as an intermediate for the production of naphthylsulfonylalkylcarboxylic acid derivatives This invention relates to naphthylthioalkylcarboxylic acid derivatives.
従来の技術
CCKはガストリン(gastrin)、セクレチン(
secret in)と並ぶ代表的な消化管ホルモンで
、特に膵外分泌刺激、胆嚢収縮等に関与するホルモンで
あることが知られている。Conventional technology CCK contains gastrin, secretin (
It is a typical gastrointestinal hormone along with secretion (secret in), and is known to be particularly involved in stimulation of exocrine pancreas, contraction of gallbladder, etc.
近年、CCKに関する研究が進められ、各種疾患におけ
るCCKの関与について解明されてきた。In recent years, research on CCK has progressed, and the involvement of CCK in various diseases has been elucidated.
その結果、特異的、競合的かつ可逆的なCCK受容体拮
抗剤が過敏性大腸炎、胆道ジスキネジー、急性膵炎など
の疾患の予防および治療剤として期待されるようになり
、注目を集めている。As a result, specific, competitive, and reversible CCK receptor antagonists are expected to be used as preventive and therapeutic agents for diseases such as irritable colitis, biliary dyskinesia, and acute pancreatitis, and are attracting attention.
発明が解決しようとする課題
本発明の目的はCCK受容体拮抗作用を有し、過敏性大
腸炎、胆道ジスキネジー、急性膵炎などの疾患の予防お
よび治療剤として有用な前記−船人(II)で表される
ナフチルスルホニルアルキルカルボン酸誘導体の製造中
間体として有用な前記−船人(1)で表されるナフチル
チオアルキルカルボン酸誘導体を提供することである。Problems to be Solved by the Invention The object of the present invention is to provide the above-mentioned Funenin (II) which has a CCK receptor antagonistic effect and is useful as a prophylactic and therapeutic agent for diseases such as irritable colitis, biliary dyskinesia, and acute pancreatitis. An object of the present invention is to provide a naphthylthioalkylcarboxylic acid derivative represented by the above-mentioned -Funenin (1), which is useful as an intermediate for the production of the represented naphthylsulfonylalkylcarboxylic acid derivative.
課題を解決するための手段
前記−船人(II)で表されるナフチルスルホニルアル
キルカルボン酸誘導体は強力なCCK受容体拮抗作用を
有し、過敏性大腸炎、胆道ジスキネジー、急性膵炎など
の疾患の予防および治療剤として有用である。Means for Solving the Problems The naphthylsulfonylalkylcarboxylic acid derivative represented by Saijin (II) has a strong CCK receptor antagonistic effect and is effective against diseases such as irritable colitis, biliary dyskinesia, and acute pancreatitis. Useful as a prophylactic and therapeutic agent.
本発明の前記−船人(I)で表されるナフチルチオアル
キルカルボン酸誘導体は、これを適当な酸化剤で酸化し
、必要に応じ加水分解あるいは加水素分解することによ
り、きわめて容易に収率よく前記−船人(II)の化合
物に導くことができる。The naphthylthioalkylcarboxylic acid derivative represented by the above-mentioned shipman (I) of the present invention can be obtained very easily in yield by oxidizing it with an appropriate oxidizing agent and hydrolyzing or hydrogenolyzing it as necessary. This can easily lead to the compound of the above-mentioned shipman (II).
本発明の一般式(I)で表されるナフチルチオアルキル
カルボン酸誘導体は新規な化合物であり、以下のように
して製造することができる。The naphthylthioalkylcarboxylic acid derivative represented by the general formula (I) of the present invention is a novel compound, and can be produced as follows.
すなわち、−船人
で表されるアミン類とを反応させることにより製造する
ことができる。That is, it can be produced by reacting with amines represented by -funerin.
本発明の一般式(I)の化合物の製造方法において出発
原料として用いられる前記−船人(In)の化合物は新
規化合物であり、以下のようにして製造することができ
る。The above-mentioned compound of Funenin (In) used as a starting material in the method for producing the compound of general formula (I) of the present invention is a new compound, and can be produced as follows.
すなわち、式
で表される2−ナフタレンチオールと、−船人(式中の
R3およびnは前記と同じ意味をもつ)で表されるナフ
チルチオアルキルカルボン酸誘導体またはその反応性官
能的誘導体と、−船人(式中のR1、R2およびYは前
記と同じ意味をもつ)(式中のAおよびBはそれぞれシ
アン基または炭素数2〜5のアルコキシカルボニル基で
あるかあるいはAが炭素数2〜5のアルコキシカルボニ
ル基でBがカルボキシ基またはそのアルカリ金属塩であ
り、nは前記と同じ意味をもつ)で表される、化合物と
をルイス塩基またはルイス酸触媒の存在下に反応して、
−船人
(式中のASBおよびnは前記と同じ意味をもつ)で表
される化合物を製し、必要に応じこれを適当な方法によ
り加水分解、モノエステル化を行うことにより得ること
ができる。That is, 2-naphthalenethiol represented by the formula; a naphthylthioalkylcarboxylic acid derivative represented by -Funenin (R3 and n in the formula have the same meanings as above) or a reactive functional derivative thereof; - Boatman (R1, R2 and Y in the formula have the same meanings as above) (A and B in the formula are each a cyan group or an alkoxycarbonyl group having 2 to 5 carbon atoms, or A is a carbon number 2 group) ~5 alkoxycarbonyl group, B is a carboxyl group or an alkali metal salt thereof, and n has the same meaning as above) in the presence of a Lewis base or Lewis acid catalyst,
- It can be obtained by preparing a compound represented by Shipin (in the formula, ASB and n have the same meanings as above), and subjecting it to hydrolysis and monoesterification by an appropriate method as necessary. .
本発明の一般式(1)で表されるナフチルチオアルキル
カルボン酸誘導体は不斉炭素を有しており、2種の光学
異性体が存在するが、本発明においてはR体、8体また
はその混合物のいずれも含まれる。The naphthylthioalkylcarboxylic acid derivative represented by the general formula (1) of the present invention has an asymmetric carbon and exists in two types of optical isomers. Any mixture is included.
発明の効果
本発明の一般式(I)で表されるナフチルチオアルキル
カルボン酸誘導体は、適当な酸化剤、例えば、m−クロ
ロ過安息香酸を用いて酸化し、必要に応じて加水分解あ
るいは加水素分解することにより極tで容易に、収率よ
く一般式(II)で表されるナフチルスルホニルアルキ
ルカルボン酸誘導体に導くことができる。Effects of the Invention The naphthylthioalkylcarboxylic acid derivative represented by the general formula (I) of the present invention is oxidized using a suitable oxidizing agent, for example, m-chloroperbenzoic acid, and if necessary, hydrolyzed or hydrolyzed. By hydrogenolysis, the naphthylsulfonylalkylcarboxylic acid derivative represented by the general formula (II) can be easily led to a high yield at extremely low temperatures.
このようにして、本発明の一般式(1)の化合物から製
造される一般式(I[)で表される化合物はCCK受容
体拮抗作用を有し、過敏性大腸炎、胆道ジスキネジー、
急性膵炎などの疾患治療剤として有用である。In this way, the compound represented by the general formula (I[) produced from the compound of the general formula (1) of the present invention has a CCK receptor antagonistic effect, and can be used to treat irritable colitis, biliary dyskinesia, etc.
It is useful as a therapeutic agent for diseases such as acute pancreatitis.
例えば、(R)−4−(N−(3−メトキシプロピル)
−Nペチルカルバモイル)−5−(2−ナフチルスルホ
ニル)ペンタン酸は125■でラベルしたCCK−8を
用いたラット摘出膵臓のCCK受容体に対するパインデ
ィングアッセイにおいて、1.2X10−’モル濃度で
50%結合抑制(IC,。〉を示し、CCK−8を用い
たモルモット摘出胆嚢での胆嚢収縮抑制試験において2
.8×10−6モル濃度で50%抑制(IC,。)を示
す。For example, (R)-4-(N-(3-methoxypropyl)
-N-petylcarbamoyl)-5-(2-naphthylsulfonyl)pentanoic acid was detected at a molar concentration of 1.2 x 10-' in a binding assay for CCK receptors in isolated rat pancreas using CCK-8 labeled with 125. % binding inhibition (IC, .) in a gallbladder contraction inhibition test using CCK-8 in a guinea pig removed gallbladder.
.. It shows 50% inhibition (IC,.) at 8 x 10-6 molar concentration.
実施例
本発明の内容を以下の参考例および実施例でさらに詳細
に説明する。なお、各参考例および実施例中の化合物の
融点はすべて未補正である。EXAMPLES The contents of the present invention will be explained in further detail with reference to the following reference examples and examples. Note that the melting points of the compounds in each Reference Example and Examples are all uncorrected.
参考例 1
4−メトキシカルボニル−2−(2−ナフチルチオメチ
ル)酪酸
2−ナフタレンチオール10.Ogと2−メチレンゲル
タロニトリル6.8mlをエタノール150mNに溶か
し、トリトンB(40%メタノール溶液)10滴を加え
たのち2時間加熱還流させた。反応液を減圧下に濃縮後
、クロロホルムで抽出し水洗したのち無水硫酸マグネシ
ウムで乾燥した。減圧下に溶媒を留去後、残留物を酢酸
玉チルーヘキサンより再結晶し、融点52〜55℃の2
−(2−ナフチルチオメチル)ゲルタロニトリル15.
6gを得た。Reference Example 1 2-naphthalenethiol 4-methoxycarbonyl-2-(2-naphthylthiomethyl)butyrate 10. Og and 6.8 ml of 2-methylene geltalonitrile were dissolved in 150 mN of ethanol, 10 drops of Triton B (40% methanol solution) were added, and the mixture was heated under reflux for 2 hours. The reaction solution was concentrated under reduced pressure, extracted with chloroform, washed with water, and dried over anhydrous magnesium sulfate. After distilling off the solvent under reduced pressure, the residue was recrystallized from acetate-chlorohexane to give 2.
-(2-naphthylthiomethyl)geltalonitrile 15.
6g was obtained.
元素分析値’ (C16)11−N2S として)0
% H% N%
計算値 72.15 5.30 10.52実
測値 71.98 5.24 10.411R
(KBr): I/CM 2245 cm−’N
MR(CDC13)
δ: 1.95〜2.3(2fl、 m)、 2.4〜
2.7(2H,m)。Elemental analysis value' (as C16)11-N2S)0
% H% N% Calculated value 72.15 5.30 10.52 Actual value 71.98 5.24 10.411R
(KBr): I/CM 2245 cm-'N
MR (CDC13) δ: 1.95~2.3 (2fl, m), 2.4~
2.7 (2H, m).
2.8〜2.95(LH,m)、 3.13(1)1.
dd、 J=7.1. 13.7Hz)、 3.3
0(IH,dd、 J=6.6゜13.7Hz)、
7.4〜7.6(3H,m)、 7.75〜80(4H
,m)
2−(2−ナフチルチオメチル)ゲルタロニトリル15
.5gを酢酸70mNに溶かし、濃塩酸70−を加え1
7時間加熱還流させた。反応液を減圧下に濃縮し、ジエ
チルエーテルを加え不溶物をろ去後、水洗したのち炭酸
水素ナトリウム水溶液を加え振り混ぜた。水層を塩酸で
酸性としたのち、ジエチルエーテルで抽出し、水洗後無
水硫酸マグネシウムで乾燥した。減圧下に溶媒を留去後
、残留物をジエチルエーテル−ヘキサンより再結晶し、
融点140〜142℃の2−(2−ナフチルチオメチル
)グルタル酸15.9gを得た。2.8-2.95 (LH, m), 3.13 (1) 1.
dd, J=7.1. 13.7Hz), 3.3
0 (IH, dd, J=6.6°13.7Hz),
7.4-7.6 (3H, m), 7.75-80 (4H
, m) 2-(2-naphthylthiomethyl)geltalonitrile 15
.. Dissolve 5g in 70mN of acetic acid, add 70m of concentrated hydrochloric acid, and add 1
The mixture was heated under reflux for 7 hours. The reaction solution was concentrated under reduced pressure, diethyl ether was added, insoluble materials were removed by filtration, and the mixture was washed with water. Then, an aqueous sodium hydrogen carbonate solution was added and the mixture was shaken. The aqueous layer was made acidic with hydrochloric acid, extracted with diethyl ether, washed with water, and dried over anhydrous magnesium sulfate. After distilling off the solvent under reduced pressure, the residue was recrystallized from diethyl ether-hexane.
15.9 g of 2-(2-naphthylthiomethyl)glutaric acid having a melting point of 140-142°C was obtained.
元素分析値: (C,6)1,504S として)0
% H%
計算値 63.14 5.30
実測値 63.37 5.34
JR(KBr): シC−Cl 1720 cm
−’NMR(DMSO−66)
δ: 1.7〜2.0(2H,m)、 2.15〜
2.4(2H,m)2.5〜2.65(LH,m)、
3.1〜3.4(2H,m)。Elemental analysis value: (C,6)1,504S)0
% H% Calculated value 63.14 5.30 Actual value 63.37 5.34 JR (KBr): C-Cl 1720 cm
-'NMR (DMSO-66) δ: 1.7~2.0 (2H, m), 2.15~
2.4 (2H, m) 2.5 to 2.65 (LH, m),
3.1-3.4 (2H, m).
7.35〜7.6(3H,m)、 7.75〜8.0
(4H,m)。7.35-7.6 (3H, m), 7.75-8.0
(4H, m).
12、32 (2H,5)
2− (2−ナフチルチオメチル)グルタルをメタノー
ル300dに溶かし、p−トルエンスルホンせた。反応
液を減圧下に濃縮後、残留物に水を加え酢酸エチルで抽
出し水洗機無水硫酸マグネシウムで乾燥した。減圧下に
溶媒を留去後、残留物をイソプロピルエーテルより再結
晶し、融点70〜71℃の4−メトキシカルボニル−2
−(2−ナフチルチオメチル)酪酸27.4gを得た。12,32 (2H,5) 2-(2-naphthylthiomethyl)glutar was dissolved in 300 d of methanol and added with p-toluenesulfone. After concentrating the reaction solution under reduced pressure, water was added to the residue, extracted with ethyl acetate, and dried over anhydrous magnesium sulfate. After distilling off the solvent under reduced pressure, the residue was recrystallized from isopropyl ether to give 4-methoxycarbonyl-2 having a melting point of 70-71°C.
27.4 g of -(2-naphthylthiomethyl)butyric acid was obtained.
元素分析値’ (CI7811+04S として)0
% H%
計算値 64.13 5.70実測値 64
.11 5.50IR (KBr): ν(
+Q 1730. 1700 cm−’NMR (
CDCl2)
δ: 1.95〜2.2(2N, m)、 2.
3〜2.5(28, m)。Elemental analysis value' (as CI7811+04S) 0
% H% Calculated value 64.13 5.70 Actual value 64
.. 11 5.50IR (KBr): ν(
+Q 1730. 1700 cm-'NMR (
CDCl2) δ: 1.95-2.2 (2N, m), 2.
3-2.5 (28, m).
2、65 〜2.8<LH, m)、 3.10(
11(、 dd, J=6、6. 13.2H
z)、 3、33(IH,dd, J=7,713
、2Hz)、 3.62(3H, s)、 7.
4 〜7.55(38m)、 7.7 〜7.9(4
H, m)参考例 2
(±)−4−メトキシカルボニル−2−(2−ナフチル
チオメチル)酪酸10.00 gをエタノール20m7
!とメタノール5rn1の混液に加熱して溶かし、(+
)−1−フェニルエチルアミン3.80gを加え室温で
放置後、析出結晶をろ取した。得られた結晶をさらにエ
タノール9−とメタノール3mlの混液に加熱して溶か
したのち室温で放置後析出した結晶をろ取し、(R)−
4−メトキシカルボニル−2−(2−ナフチルチオメチ
ル)酪酸と(+)−1−フェニルエチルアミントノ塩2
、88gを得た。この塩0.72gに2規定塩酸10m
lを加え酢酸エチルで抽出し、水洗機無水硫酸マグネシ
ウムで乾燥した。減圧下に溶媒を留去後、残留物をイソ
プロピルエーテルより再結晶し、融点72〜74℃の(
R)−4−メトキシカルボニル−2−(2−ナフチルチ
オメチル)酪酸0.37gを得た。2,65 ~2.8<LH, m), 3.10(
11(, dd, J=6, 6. 13.2H
z), 3, 33 (IH, dd, J=7,713
, 2Hz), 3.62 (3H, s), 7.
4 ~ 7.55 (38m), 7.7 ~ 7.9 (4
H, m) Reference Example 2 10.00 g of (±)-4-methoxycarbonyl-2-(2-naphthylthiomethyl)butyric acid was added to 20 m7 of ethanol.
! Heat and dissolve in a mixture of 5rn1 of methanol and (+
)-1-phenylethylamine (3.80 g) was added, and the mixture was allowed to stand at room temperature, and the precipitated crystals were collected by filtration. The obtained crystals were further heated and dissolved in a mixture of 9 ml of ethanol and 3 ml of methanol, and after being left at room temperature, the precipitated crystals were collected by filtration to give (R)-
4-Methoxycarbonyl-2-(2-naphthylthiomethyl)butyric acid and (+)-1-phenylethylamine salt 2
, 88g was obtained. 10 m of 2N hydrochloric acid to 0.72 g of this salt
The mixture was washed with water and dried over anhydrous magnesium sulfate. After distilling off the solvent under reduced pressure, the residue was recrystallized from isopropyl ether to give (
0.37 g of R)-4-methoxycarbonyl-2-(2-naphthylthiomethyl)butyric acid was obtained.
比旋光度: [αL +46.8°(Cm1.50,
MeOH)IR (KBr): νc+o 1
740, 1725, 1690 Cm−’NMR (
CDCl2)
ラセミ体と一致
一方、(+)−1−フェニルエチルアミンとの塩の最初
のる液を濃縮後残留物をエタノールより3回再結晶をく
り返すことにより、(S)−4−メトキシカルボニル−
2−(2−ナフチルチオメチル)酪酸と(+)−1−フ
ェニルエチルアミンとの塩1.04gを得た。この塩0
.90gに2規定塩酸15ff+7!を加え酢酸エチル
で抽出し、水洗機無水硫酸マグネシウムで乾燥した。Specific optical rotation: [αL +46.8° (Cm1.50,
MeOH)IR (KBr): νc+o 1
740, 1725, 1690 Cm-'NMR (
CDCl2) Same as the racemate On the other hand, after concentrating the first solution of the salt with (+)-1-phenylethylamine, the residue was recrystallized three times from ethanol to obtain (S)-4-methoxycarbonyl. −
1.04 g of a salt of 2-(2-naphthylthiomethyl)butyric acid and (+)-1-phenylethylamine was obtained. This salt 0
.. 2N hydrochloric acid 15ff+7 for 90g! was added, extracted with ethyl acetate, and dried over anhydrous magnesium sulfate.
減圧下に溶媒を留去後、残留物をイソプロピルエーテル
より再結晶し、(S)−4−メトキシカルボニル2−(
2−ナフチルチオメチル)酪酸0.46gを得た。After distilling off the solvent under reduced pressure, the residue was recrystallized from isopropyl ether to give (S)-4-methoxycarbonyl 2-(
0.46 g of 2-naphthylthiomethyl)butyric acid was obtained.
比旋光度: 〔(X) D− 45.6°(Cm1.
07, MeOH)融点、IRおよびNMRは(R)体
と一致した。Specific optical rotation: [(X) D- 45.6° (Cm1.
07, MeOH) melting point, IR and NMR were consistent with the (R) form.
参考例 3
2−(2−ナフチルチオメチル)グルタル酸14.0g
をアセトニトリル180 mjに溶かし、ベンジルアル
コール57rnlおよびp− )ルエンスルホン酸0.
52gを加え23時間加熱還流させた。反応液を減圧下
に濃縮し、残留物をシリカゲルフラッシュカラムクロマ
トグラフィー(溶出溶媒:塩化メチレン/メタノール=
70/1)で精製後、酢酸エチル−ヘキサンより再結晶
し、融点94〜95℃の4−ベンジルオキシカルボニル
−2−(2−ナフチルチオメチル)酪酸11.Ogを得
た。Reference example 3 2-(2-naphthylthiomethyl)glutaric acid 14.0g
was dissolved in 180 mj of acetonitrile, 57 mj of benzyl alcohol and 0.0 mj of p-)luenesulfonic acid.
52 g was added and heated under reflux for 23 hours. The reaction solution was concentrated under reduced pressure, and the residue was subjected to silica gel flash column chromatography (elution solvent: methylene chloride/methanol =
70/1) and recrystallized from ethyl acetate-hexane to give 4-benzyloxycarbonyl-2-(2-naphthylthiomethyl)butyric acid 11. Obtained Og.
元素分析値: (C23H2□04S として)0%
H%
計算値 70.03 5.62実測値 70
.05 5.69IR(KBr): vc−
o 1730. 1700 cmNMR(CDCl
2)
δ: 1.’lJ〜2.2(2H,m)、 2.3
〜2.55(28,m)。Elemental analysis value: (as C23H2□04S) 0%
H% Calculated value 70.03 5.62 Actual value 70
.. 05 5.69IR (KBr): vc-
o 1730. 1700 cmNMR (CDCl
2) δ: 1. 'lJ~2.2 (2H, m), 2.3
~2.55 (28, m).
2.65〜2.8(IH,m)、 3.09(1)1
. dd、 J6.6. 13.2)1z)、
3.26(1’H,dd、 J=7.7゜13.2)
1z)、 5.09(2)1. s)、 7.2
〜7.5(8fl。2.65-2.8 (IH, m), 3.09 (1) 1
.. dd, J6.6. 13.2)1z),
3.26 (1'H, dd, J=7.7°13.2)
1z), 5.09(2)1. s), 7.2
~7.5 (8fl.
m)、 7.65〜7.85 (4H,m)参考例
4
2−ナフタレンチオール0.38gと3−メトキシカル
ボニル−2−メチレンプロピオン酸ナトリウム0.39
gをメタノール20mNに溶かし、トリトンB (40
%メタノール溶液)10滴を加えたのち12時間加熱還
流させた。反応液を減圧下に濃縮後、希塩酸で酸性とし
酢酸エチルで抽出したのち水で洗い、無水硫酸マグネシ
ウムで乾燥した。減圧下に溶媒を留去し、残留物をシリ
カゲル中圧液体カラムクロマトクラフィー(溶出溶媒:
クロロポルム/メタ/ −ル=20/1)で精製後、イ
ソプロピルエーテルより再結晶し融点97〜99℃の2
−メトキシカルボニルメチル−3−(2−ナフチルチオ
)プロピオン酸0.38gを得た。m), 7.65-7.85 (4H, m) Reference example
4 0.38 g of 2-naphthalenethiol and 0.39 g of sodium 3-methoxycarbonyl-2-methylenepropionate
Dissolve g in methanol 20mN, Triton B (40
% methanol solution) were added thereto, and the mixture was heated under reflux for 12 hours. The reaction solution was concentrated under reduced pressure, acidified with dilute hydrochloric acid, extracted with ethyl acetate, washed with water, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was subjected to silica gel medium pressure liquid column chromatography (elution solvent:
After purification with chloroporum/meth/-ol = 20/1), it was recrystallized from isopropyl ether to give 2.
0.38 g of -methoxycarbonylmethyl-3-(2-naphthylthio)propionic acid was obtained.
元素分析値’ (C+gH1604Sとして)0%
H%
63.14 5.30
63.12 5.27
シc+o 1735.1700 cm計算値
実測値
IR(KBr):
NMR(CDCl2)
δ: 2.7〜2.9(2H,m)、 3.0 〜3
.25(2H,m)。Elemental analysis value' (as C+gH1604S) 0%
H% 63.14 5.30 63.12 5.27 c+o 1735.1700 cm Calculated value Actual value IR (KBr): NMR (CDCl2) δ: 2.7-2.9 (2H, m), 3. 0 to 3
.. 25 (2H, m).
3.47(LH,dd、 J=5.0.13.2Hz)
、 3.64(3H,s)、 7.4〜7.55(3H
,m)、 7.7〜7.9(4H,m)
実施例
4−メトキシカルボニル−2−(2−ナフチルチオメチ
ル)酪酸4.Ogを乾燥塩化メチレン80mNに溶かし
、塩化チオニル4.Omlを加え2時間加熱還流させた
。3.47 (LH, dd, J=5.0.13.2Hz)
, 3.64 (3H, s), 7.4~7.55 (3H
, m), 7.7-7.9 (4H, m) Example 4-Methoxycarbonyl-2-(2-naphthylthiomethyl)butyric acid 4. Dissolve Og in 80 mN of dry methylene chloride and add 4.0 mN of thionyl chloride. Oml was added and the mixture was heated under reflux for 2 hours.
反応液を減圧下に濃縮乾固し、油状の残留物を得た。こ
の残留物の乾燥塩化メチレン20m1溶液を、ジペンチ
ルアミン3.5−およびトリエチルアミン5.4rn1
の乾燥塩化メチレン80mA溶液に、水冷撹拌下に滴下
したのち、室温で16時間反応させた。反応液を希塩酸
、水、炭酸水素す) IJウム水溶液および水で順次洗
ったのち無水硫酸マグネシウムで乾燥した。減圧下に溶
媒を留去後、残留物をシリカゲル中圧液体カラムクロマ
トグラフィー(溶出溶媒:塩化メチレン)で精製し、油
状の4−(N、Nジベンチル力ルバモイル) −5−(
2−ナフチルチオ)ペンタン酸メチル5.1gを得た。The reaction solution was concentrated to dryness under reduced pressure to obtain an oily residue. A solution of this residue in 20 ml of dry methylene chloride was dissolved in 3.5 ml of dipentylamine and 5.4 ml of triethylamine.
The mixture was added dropwise to an 80 mA solution of dry methylene chloride under water cooling and stirring, and then reacted at room temperature for 16 hours. The reaction solution was washed successively with dilute hydrochloric acid, water, hydrogen carbonate aqueous solution, and water, and then dried over anhydrous magnesium sulfate. After evaporating the solvent under reduced pressure, the residue was purified by medium pressure liquid column chromatography on silica gel (elution solvent: methylene chloride) to obtain an oily 4-(N,N dibentylrubamoyl)-5-(
5.1 g of methyl 2-naphthylthio)pentanoate was obtained.
IR(neat)’ vc−o 1735.164
0 cm−’NMR(CDC13)
δ: 0.66(3)1. t、 J=7.1Hz)、
0.8〜1.05(7H。IR(neat)' vc-o 1735.164
0 cm-'NMR (CDC13) δ: 0.66 (3) 1. t, J=7.1Hz),
0.8-1.05 (7H.
m)、 1.15〜1.6(8H,m)、 2.0〜2
.5(4H。m), 1.15-1.6 (8H, m), 2.0-2
.. 5 (4H.
m)、 2.85〜3.4(7H,m)、 3.63(
3)1. s)。m), 2.85-3.4 (7H, m), 3.63 (
3)1. s).
7.4〜7.55(3H,m)、 7.7〜7.85(
4H,m)実施例 2
実施例1と同様にして表の化合物(油状)を製造した。7.4-7.55 (3H, m), 7.7-7.85 (
4H, m) Example 2 The compounds shown in the table (oil) were produced in the same manner as in Example 1.
ただし、比旋光度が無記載の化合物はラセミ体である。However, compounds whose specific rotation is not listed are racemic.
参考例 5
(R)−4−〔N−(3−メトキシプロピル)−N−ペ
ンチルカルバモイル)−5−(2−ナフチルチオ)ペン
タン酸メチル42.7gを乾燥クロロホルム500−に
溶かし、水冷撹拌下にm−り四口過安息呑酸(80%)
50gを少量ずつ加えたのち、室温で2時間反応させた
。反応液に亜硫酸ナトリウムを加えたのち、炭酸水素ナ
トリウム水溶液および水で順次洗い無水硫酸マグネシウ
ムで乾燥した。減圧下に溶媒を留去し、油状の(R)−
4−〔N−(3−メトキシプロピル)−N−ペンチルカ
ルバモイル)−5−(2−ナフチルスルホニル)ペンタ
ン酸メチル42.0gを得た。Reference Example 5 42.7 g of methyl (R)-4-[N-(3-methoxypropyl)-N-pentylcarbamoyl)-5-(2-naphthylthio)pentanoate was dissolved in 500 g of dry chloroform and stirred under water cooling. m-ri four mouth perbenzoic acid (80%)
After adding 50 g little by little, the mixture was reacted at room temperature for 2 hours. After adding sodium sulfite to the reaction solution, the mixture was washed successively with an aqueous sodium bicarbonate solution and water, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain an oily (R)-
42.0 g of methyl 4-[N-(3-methoxypropyl)-N-pentylcarbamoyl)-5-(2-naphthylsulfonyl)pentanoate was obtained.
比旋光度: 〔α) n ” 9.4°(C=1.1
5. MeOH)IR(neaj)=I’c−o 1
730.1630 cm−’νso 1305.11
50 (m−1HMR(CDCl2)
δ: 0.86 and 0.92(3H,t、
J=6.9Hz)、 1 1〜2.1(IOH,
m)、 2.25〜2.4(2H,m)、 3.0
〜3.5(IIH,m)、 3.63 and
3.64(3)1. s)3.84 and 3
.90(1)1. dd、 J=7.9゜13.9
Hz)、 7.55〜7.7(2H,m)、 7.
8〜8、05(4H,m)、 8.48(IH,5)
(R)−4−[N−(3−メトキシプロピル)−N−ペ
ンチルカルバモイル)−5−(2−ナフチルスルホニル
)ペンタン酸メチル42.0gをメタノール460mg
および水150 mi2の混液に溶かし、1規定水酸化
ナトリウム水溶液86mNを滴下後、室温で3時間反応
させた。Specific optical rotation: [α) n” 9.4° (C=1.1
5. MeOH)IR(neaj)=I'c-o 1
730.1630 cm-'νso 1305.11
50 (m-1 HMR (CDCl2) δ: 0.86 and 0.92 (3H, t,
J=6.9Hz), 1 1~2.1(IOH,
m), 2.25-2.4 (2H, m), 3.0
~3.5 (IIH, m), 3.63 and
3.64(3)1. s) 3.84 and 3
.. 90(1)1. dd, J=7.9°13.9
Hz), 7.55-7.7 (2H, m), 7.
8-8, 05 (4H, m), 8.48 (IH, 5)
42.0 g of methyl (R)-4-[N-(3-methoxypropyl)-N-pentylcarbamoyl)-5-(2-naphthylsulfonyl)pentanoate was added to 460 mg of methanol.
The mixture was dissolved in a mixed solution of 150 mi2 of water and 86 mN of a 1N aqueous sodium hydroxide solution was added dropwise thereto, followed by reaction at room temperature for 3 hours.
反応液に希塩酸を加えpH4としたのち、減圧下に濃縮
した。残留物に水を加え酢酸エチルで抽出し、水洗後無
水硫酸マグネシウムで乾燥した。減圧下に溶媒を留去後
、残留物を酢酸エチル−イソプロピルエーテルより再結
晶し、融点68〜70℃の(R)−4−〔N−(3−メ
トキシプロピル)−N−ペンチルカルバモイル]−5−
(2−ナフチルスルホニル)ペンタン酸29.4gを得
た。The reaction solution was adjusted to pH 4 by adding diluted hydrochloric acid, and then concentrated under reduced pressure. Water was added to the residue, extracted with ethyl acetate, washed with water, and dried over anhydrous magnesium sulfate. After evaporating the solvent under reduced pressure, the residue was recrystallized from ethyl acetate-isopropyl ether to give (R)-4-[N-(3-methoxypropyl)-N-pentylcarbamoyl]- with a melting point of 68 to 70°C. 5-
29.4 g of (2-naphthylsulfonyl)pentanoic acid was obtained.
元素分析値: (C2SH3SNO6Sとして)0%
N% N%
計算値 62.87 7.39 2.93実
測値 62.64 7.17 2.90比旋
光度: 〔αL−24,5°(C=1.47゜ジオキサ
ン)
IR(Kart: vc−o 1730.164
0 cm−’ν、。 1305.1150 cm−’N
MR(CDC13)
δ: 0.86 and 0.90(3H,t、 J
=7.1Hz)、 1.1〜2、15(10ft、
m)、 2.38(2H,t、 J=6.6Hz)。Elemental analysis value: (as C2SH3SNO6S) 0%
N% N% Calculated value 62.87 7.39 2.93 Actual value 62.64 7.17 2.90 Specific optical rotation: [αL-24.5° (C = 1.47° dioxane) IR (Kart: vc-o 1730.164
0 cm-'ν,. 1305.1150 cm-'N
MR (CDC13) δ: 0.86 and 0.90 (3H, t, J
=7.1Hz), 1.1~2, 15 (10ft,
m), 2.38 (2H, t, J=6.6Hz).
3.0〜3.55(11)1. m)、 3.75
〜3.95(IH。3.0-3.55 (11)1. m), 3.75
~3.95 (IH.
Claims (1)
7のアルコキシカルボニル基、N−モノ置換またはN,
N−ジ置換カルバモイル基、炭素数1〜6のアルキル基
または炭素数1〜6のアルコキシ基であり、R^2は炭
素数1〜10のアルキル基であり、R^3は炭素数1〜
4のアルキル基またはベンジル基であり、Yは炭素数1
〜4のアルキレン基であり、nは1または2である)で
表されるナフチルチオアルキルカルボン酸誘導体。[Claims] General formula ▲ Numerical formula, chemical formula, table, etc. ▼ (R^1 in the formula is a hydrogen atom, a carboxy group, a carbon number of 2 to
7 alkoxycarbonyl group, N-monosubstituted or N,
N-disubstituted carbamoyl group, an alkyl group having 1 to 6 carbon atoms, or an alkoxy group having 1 to 6 carbon atoms, R^2 is an alkyl group having 1 to 10 carbon atoms, and R^3 is an alkyl group having 1 to 10 carbon atoms.
4 alkyl group or benzyl group, Y has 1 carbon number
~4 alkylene group, n is 1 or 2).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2211891A JP2520776B2 (en) | 1990-08-10 | 1990-08-10 | Naphthylthioalkylcarboxylic acid derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2211891A JP2520776B2 (en) | 1990-08-10 | 1990-08-10 | Naphthylthioalkylcarboxylic acid derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0495062A true JPH0495062A (en) | 1992-03-27 |
JP2520776B2 JP2520776B2 (en) | 1996-07-31 |
Family
ID=16613353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2211891A Expired - Lifetime JP2520776B2 (en) | 1990-08-10 | 1990-08-10 | Naphthylthioalkylcarboxylic acid derivatives |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2520776B2 (en) |
-
1990
- 1990-08-10 JP JP2211891A patent/JP2520776B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2520776B2 (en) | 1996-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4803946B2 (en) | Substituted phenylpropionic acid derivatives | |
JP2001055367A (en) | Substituted phenylpropionic acid derivative as alfa- agonist to human peroxysome proliferator-activated receptor(ppar) | |
JPH1053577A (en) | Substituted 4-(quinolin-2-yl-methoxy)phenylacetic acid derivative and salt thereof | |
JPS62175461A (en) | Cholecystokinin (cck) antagonist | |
Hoffman et al. | The stereoselective synthesis of 2-alkyl. gamma.-keto acid and heterocyclic ketomethylene peptide isostere core units using chiral alkylation by 2-triflyloxy esters | |
US20060135785A1 (en) | Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof | |
US5317021A (en) | 3-mercapto-glutamic acid derivatives | |
JPH0495062A (en) | Naphthylthioalkylcarboxylic acid derivative | |
JPH0672866A (en) | Differentiation inducing agent | |
US6610855B2 (en) | Synthesis of 3-amino-3-aryl propanoates | |
DeGraw et al. | Potential Anticancer Agents. 1 LXXIV. Alkylating Agents Derived from Indole. III. Synthesis of Some Indolealkanoic Acid Nitrogen Mustards | |
JP2520777B2 (en) | Arylthioalkylcarboxylic acid derivatives | |
IE65279B1 (en) | Process for the preparation of dextrorotatory 3-(3-pyridyl)-1h,3h-pyrrolo[1,2-c]-7-thiazolecarbo xylic acid | |
FR2703679A1 (en) | New perhydroisoindole derivatives, their preparation and pharmaceutical compositions containing them. | |
JP2510893B2 (en) | Naphthylsulfonylalkylcarboxylic acid derivatives | |
JPH0495064A (en) | Naphthylthioalkylcarboxylic acid derivative | |
JPH0495061A (en) | Phenylthioalkylcarboxylic acid derivative | |
JPH07196626A (en) | New benzimidazole derivative | |
JP2686876B2 (en) | Novel succinic acid derivative | |
JPH05125038A (en) | Phenoxyalkanoic acid derivative and its production | |
JPH0495063A (en) | Naphthylthioalkylcarboxylic acid derivative | |
JPH0495060A (en) | Dichlorophenylthioalkylcarboxylic acid derivative | |
SU812170A3 (en) | Method of preparing-substituted 2,4-bis'(benzamido)-benzoyl amides | |
JPH03151355A (en) | Phenylsulfonylalkylcarboxylic acid derivative | |
JPH03193756A (en) | Naphthyl sulfonyl alkylcarboxylic acid derivative |